-
PHILADELPHIA, Pennsylvania New cardiac markers such as troponin I, troponin T and, most recently, B-type natriuretic peptide (BNP) and proBNP, have revolutionized the diagnosis of myocardial infarction and heart failure in the emergency department.
-
Guidants (Indianapolis, Indiana) Vascular Intervention division (Santa Clara, California) has acquired the right to use certain bioabsorbable polymer technologies developed by MediVas (San Diego, California), a firm that primarily focuses on developing technologies for diagnosis and treatment of cardiovascular diseases.
-
Novoste (Norcross, Georgia), a specialist in brachytherapy technology for the prevention of in-stent restenosis, reported last month that it would lay off 50 employees, mostly at its Norcross location, in ongoing moves to cut costs and restructure operations.
-
Cardiac Science (Irvine, California) and GE Medical Systems Information Technologies (GEMSIT; Milwaukee, Wisconsin) have signed multi-year strategic OEM, distribution and development agreements, under which GE will market Cardiac Science automated external defibrillators (AEDs) and fully-automatic in-hospital defibrillator-monitors (CRMs) under the GE name in Europe, Asia, the Middle East and other international markets.
-
A new filter device designed to capture the emboli and aortic plaque caused by cross-clamping of the aorta during a cardiopulmonary bypass procedure began commercial launch in the U.S. last month, and could potentially benefit hundreds of thousands of patients worldwide. Edwards Lifesciences (Irvine, California) said it has begun U.S. launch of the Embol-X intra-aortic embolic management system.
-
-
To provide you with critical information on the updated regulations from the Centers for Medicare and Medicaid Services, Thomson American Health Consultants offers "New EMTALA Regulations: Are They Too Good to be True?" an audio conference on Tuesday, Oct. 21, from 2:30-3:30 p.m. ET.
-
EMTALA: The Essential Guide to Compliance from Thomson American Health Consultants, publisher of Emergency Medicine Reports, explains how the changes to EMTALA will affect emergency departments and off-campus clinics. In-depth articles, at-a-glance tables, and Q-and-A discussions of real-life situations are presented, and key differences between the old EMTALA and the new changes are succinctly explained.
-
Dizziness and vertigo are among the most common complaints seen by neurologists, and benign paroxysmal positional vertigo is one of their most frequent causes.
-
Urinary Tetrahydroaldosterone as a Screen for Primary Aldosteronism; Finasteride and Prostate Cancer; Impermeable Bed Covers in Patients with Allergic Rhinitis
